nash
(2)
The Tiny Biotech Betting a Lab-Grown Liver Can Tell Pharma Which Drugs Will Fail
Drug development still asks mice to predict people. Viscient’s nine-person team is building human liver disease in a dish - then using it to decide which medicines deserve a clinical trial.
Allysta Pharmaceuticals, Inc.
Allysta Pharmaceuticals is a private, venture-backed, clinical-stage biopharmaceutical company developing first-in-class therapeutic peptides that target adiponectin signaling. Its lead compound, ALY688, is described as the first adiponectin receptor agonist to enter human testing, with anti-inflammatory, anti-fibrotic, cell-regenerative and metabolic properties. Allysta is advancing ALY688 as an ophthalmic solution for dry eye disease and as an extended/sustained-release formulation for systemic conditions such as NASH/MASH and Duchenne muscular dystrophy.